Inici › Limfoma de Burkitt › Missouri
Assaigs clínics de Limfoma de Burkitt a Missouri
8 estudis de Limfoma de Burkitt busquen participants en centres de Missouri.
Ciutats de Missouri
Text oficial de l'estudi (anglès)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
ReclutantFase 2
366 Days – 46 Years · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- i 3 més
ReclutantFase 3
Edats de 18 a 39 · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- i 4 més
ReclutantFase 2
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 29 de set. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
ReclutantFase 2
365 Days · Tots els sexes · Actualitzat el 25 de set. 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Mercy Hospital ( Site 1024), Kansas City
ReclutantFase 1/2
6 Months – 25 Years · Tots els sexes · Actualitzat el 17 de set. 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- Washington University School of Medicine, St Louis
- i 1 més
ReclutantFase 2
Edats de 1 a 30 · Tots els sexes · Actualitzat el 1 de set. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- i 2 més
ReclutantFase 3
365 Days – 25 Years · Tots els sexes · Actualitzat el 25 d’ag. 2026 · NCT03959085The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Mercy Hospital, Kansas City
ReclutantFase 2
Edats de 1 a 25 · Tots els sexes · Actualitzat el 4 de maig 2025 · NCT03509961De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.